Year: 2017
Type: review
Abstract: Antiretroviral therapy (ART) has rendered HIV-1 infection a treatable illness; however, ART is not curative owing to the persistence of replication-competent, latent proviruses in long-lived resting T cells. Strategies that target these latently infected cells and allow immune recognition and clearance of this reservoir will be necessary to eradicate HIV-1 in infected individuals. This review describes current pharmacologic approaches to reactivate the latent reservoir so that infected cells can be recognized and targeted, with the ultimate goal of achieving an HIV-1 cure.
Source: Annual Review of Medicine
Authors: Adam M. Spivak, Vicente Planelles
Institution: University of Utah
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Awards: G1222720780, BEAT-HIV: Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy, G3245697546, Preclinical Development of Ingenol and HDACi Toward HIV Eradication, Development of SMAC mimetics as latency-reversing agents, The Effects of ART on Platelets and HIV-Associated Thrombosis, Preclinical Development of Ingenol and HDACi Toward HIV Eradication
OpenAlex ID: W2736822140